Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma
Author:
Affiliation:
1. Division of Hematology; Mayo Clinic; Rochester MN USA
2. Dana-Farber Cancer Institute; Boston MA USA
3. Millennium Pharmaceuticals, Inc.; Cambridge MA USA
Funder
Millennium Pharmaceuticals, Inc.
Janssen Global Services LLC
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14754/fullpdf
Reference56 articles.
1. Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model;Ale;Experimental Neurology,2014
2. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature;Argyriou;Blood,2008
3. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma;Arnulf;Haematologica,2012
4. Good publication practice for communicating company-sponsored medical research: GPP3;Battisti;Annals of Internal Medicine,2015
5. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma;Bensinger;British Journal of Haematology,2010
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article;Blood and Lymphatic Cancer: Targets and Therapy;2023-09
2. Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma;Haematologica;2023-08-24
3. The nonlinear association between red blood cell distribution width (RDW) and bortezomib-related peripheral neurotoxicity (PN): A retrospective cohort study;Heliyon;2023-05
4. Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review;British Journal of Haematology;2022-07-07
5. Current approaches to management of newly diagnosed multiple myeloma;American Journal of Hematology;2022-03-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3